Aimmune Therapeutics Inc.
www.aimmune.com
Latest From Aimmune Therapeutics Inc.
Aimmune’s Palforzia Gains US FDA Panel Nod But Faces REMS Restrictions
The agency’s plan to require a Risk Evaluation and Mitigation Strategy aimed at systemic allergic reactions with the peanut allergy immunotherapy did not go far enough, advisory committee members said, pushing for additional measures to be folded into the program.
Aimmune’s Peanut Allergy Immunotherapy Brings Safety Concerns To US FDA Panel
Palforzia was associated with a higher rate of adverse events, systemic allergic reactions, eosinophilic esophagitis and epinephrine use in controlled clinical trials; Allergenic Products Advisory Committee will weigh approval for patients ages 4-17 years with confirmed peanut allergy diagnosis.
Keeping Track: Amarin And Nektar Signal Delays, DBV Returns, And Provention Notches A BTD
The latest drug development news and highlights from our US FDA Performance Tracker.
Finance Watch: NGM Bio Is Second NASH IPO In Two Weeks
Public Company Edition: NGM went public a week after Genfit, but endured a rockier start, trading below its IPO price. Also, Blueprint, Tricida and Sangamo launch large offerings after positive clinical and regulatory updates.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Vaccines
- Therapeutic Areas
- Immune Disorders
- Alias(es)
- Allergen Research Corp.
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Aimmune Therapeutics Inc.
- Senior Management
-
Jayson Dallas, Pres. & CEO
Eric Bjerkholt, CFO
Jeffrey H Knapp, PhD, COO
Daniel C Adelman, MD, CMO
Mary Rozenman, PhD, SVP, Corp. Dev. & Strategy - Contact Info
-
Aimmune Therapeutics Inc.
Phone: (650) 614-5220
8000 Marina Blvd.
Ste. 300
Brisbane, CA 94005
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice